144 related articles for article (PubMed ID: 17560621)
1. Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.
Derby NR; Gray S; Wayner E; Campogan D; Vlahogiannis G; Kraft Z; Barnett SW; Srivastava IK; Stamatatos L
Virology; 2007 Sep; 366(2):433-45. PubMed ID: 17560621
[TBL] [Abstract][Full Text] [Related]
2. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
[TBL] [Abstract][Full Text] [Related]
3. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
[TBL] [Abstract][Full Text] [Related]
4. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.
Krachmarov CP; Honnen WJ; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
J Virol; 2006 Jul; 80(14):7127-35. PubMed ID: 16809318
[TBL] [Abstract][Full Text] [Related]
5. Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.
Kraft Z; Strouss K; Sutton WF; Cleveland B; Tso FY; Polacino P; Overbaugh J; Hu SL; Stamatatos L
J Virol; 2008 Jun; 82(12):5912-21. PubMed ID: 18400850
[TBL] [Abstract][Full Text] [Related]
6. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
[TBL] [Abstract][Full Text] [Related]
7. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
Stamatatos L; Lim M; Cheng-Mayer C
AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360
[TBL] [Abstract][Full Text] [Related]
8. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
Ching LK; Vlachogiannis G; Bosch KA; Stamatatos L
J Virol; 2008 Jan; 82(2):949-56. PubMed ID: 18003732
[TBL] [Abstract][Full Text] [Related]
9. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
Srivastava IK; VanDorsten K; Vojtech L; Barnett SW; Stamatatos L
J Virol; 2003 Feb; 77(4):2310-20. PubMed ID: 12551968
[TBL] [Abstract][Full Text] [Related]
10. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
[TBL] [Abstract][Full Text] [Related]
11. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.
Srivastava IK; Stamatatos L; Kan E; Vajdy M; Lian Y; Hilt S; Martin L; Vita C; Zhu P; Roux KH; Vojtech L; C Montefiori D; Donnelly J; Ulmer JB; Barnett SW
J Virol; 2003 Oct; 77(20):11244-59. PubMed ID: 14512572
[TBL] [Abstract][Full Text] [Related]
12. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
[TBL] [Abstract][Full Text] [Related]
13. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
[TBL] [Abstract][Full Text] [Related]
14. Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.
Ching L; Stamatatos L
J Virol; 2010 Oct; 84(19):9932-46. PubMed ID: 20660181
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
[TBL] [Abstract][Full Text] [Related]
16. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.
Edinger AL; Ahuja M; Sung T; Baxter KC; Haggarty B; Doms RW; Hoxie JA
J Virol; 2000 Sep; 74(17):7922-35. PubMed ID: 10933700
[TBL] [Abstract][Full Text] [Related]
17. Characterization of monoclonal antibodies to human immunodeficiency virus type 2 envelope glycoproteins.
Traincard F; Rey-Cuillé MA; Huon I; Dartevelle S; Mazié JC; Benichou S
AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1659-67. PubMed ID: 7888225
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.
Alsmadi O; Tilley SA
J Virol; 1998 Jan; 72(1):286-93. PubMed ID: 9420226
[TBL] [Abstract][Full Text] [Related]
19. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
Earl PL; Broder CC; Long D; Lee SA; Peterson J; Chakrabarti S; Doms RW; Moss B
J Virol; 1994 May; 68(5):3015-26. PubMed ID: 7512157
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
